Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 10/2017

01-10-2017 | Review Article

The Role of GABA Receptor Agonists in Anesthesia and Sedation

Authors: Janette Brohan, Basavana G. Goudra

Published in: CNS Drugs | Issue 10/2017

Login to get access

Abstract

GABA (γ-aminobutyric acid) receptors, of which there are two types, are involved in inhibitory synapses within the central nervous system. The GABAA receptor (GABAAR) has a central role in modern anesthesia and sedation practice, which is evident from the high proportion of agents that target the GABAAR. Many GABAAR agonists are used in anesthesia practice and sedation, including propofol, etomidate, methohexital, thiopental, isoflurane, sevoflurane, and desflurane. There are advantages and disadvantages to each GABAAR agonist currently in clinical use. With increasing knowledge regarding the pharmacology of GABAAR agonists, however, newer sedative agents have been developed which employ ‘soft pharmacology’, a term used to describe the pharmacology of agents whereby their chemical configuration allows rapid metabolism into inactive metabolites after the desired therapeutic effect(s) has occurred. These newer ‘soft’ GABAAR agonists may well approach ideal sedative agents, as they can offer well-controlled, titratable activity and ultrashort action. This review provides an overview of the role that GABAAR agonists currently play in sedation and anesthesia, in addition to discussing the future role of novel GABAAR agonists in anesthesia and sedation.
Literature
1.
Whiting PJ. GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery? Drug Discov Today. 2003;8:445–50.PubMedCrossRef
2.
Cossart R, Bernard C, Ben-Ari Y. Multiple facets of GABAergic neurons and synapses: multiple fates of GABA signalling in epilepsies. Trends Neurosci. 2005;28(2):108–15.PubMedCrossRef
3.
Nutt D. GABAA receptors: subtypes, regional distribution, and function. J Clin Sleep Med. 2006;2(2):S7–11.PubMed
4.
Connolly CN, Krishek BJ, McDonald B, Smart TG, Moss SJ. Assembly and cell surface expression of heteromeric and homomeric g-aminobutyric acid type A receptors. J Biol Chem. 1996;271(1):89–96.PubMedCrossRef
5.
Mody I, Pearce RA. Diversity of inhibitory neurotransmission through GABA(A) receptors. Trends Neurosci. 2004;27:569–75.PubMedCrossRef
6.
Sivilotti L, Nistri A. GABA receptor mechanisms in the central nervous system. Prog Neurobiol. 1991;36(1):35–92.PubMedCrossRef
7.
Antkowiak B, Kirschfeld K. Neural mechanisms of anesthesia [in German]. Anasthesiol Intensivmed. 2000;35:731–43.CrossRef
8.
Collins JG, Kendig JJ, Mason P. Anesthetic actions within the spinal cord: contributions to the state of general anesthesia. Trends Neurosci. 1995;18:549–53.PubMedCrossRef
9.
McGaugh JL, Izquierdo I. The contribution of pharmacology to research on the mechanisms of memory formation. Trends Pharmacol Sci. 2000;21:208–10.PubMedCrossRef
10.
McKernan RM, Rosahl TW, Reynolds DS, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci. 2000;3:587–92.PubMedCrossRef
11.
Low K, Crestani F, Keist R, et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science. 2000;290:131–4.PubMedCrossRef
12.
Chen K, Li HZ, Ye N, Zhang J, Wang JJ. Role of GABAB receptors in GABA and baclofen-induced inhibition of adult rat cerebellar interpositus nucleus neurons in vitro. Brain Res Bull. 2005;67(4):310–8.PubMedCrossRef
13.
Dimitrijevic N, Dzitoyeva S, Satta R, et al. Drosophila GABA(B) receptors are involved in behavioral effects of gamma-hydroxybutyric acid (GHB). Eur J Pharmacol. 2005;519(3):246–52.PubMedCrossRef
14.
Dzitoyeva S, Dimitrijevic N, Manev H. Gamma-aminobutyric acid B receptor 1 mediates behavior-impairing actions of alcohol in Drosophila: adult RNA interference and pharmacological evidence. Proc Natl Acad Sci USA. 2003;100(9):5485–90.PubMedPubMedCentralCrossRef
15.
Manev H, Dimitrijevic N. Drosophila model for in vivo pharmacological analgesia research. Eur J Pharmacol. 2004;491(2–3):207–8.PubMedCrossRef
16.
Brogden RN, Speight TM, Avery GS. Baclofen: a preliminary report of its pharmacological properties and therapeutic efficacy in spasticity. Drugs. 1974;8(1):1–14.PubMedCrossRef
17.
18.
Franks NP, Lieb WR. Molecular and cellular mechanisms of general anaesthesia. Nature. 1994;367:607–14.PubMedCrossRef
19.
Sanna E, Garau F, Harris RA. Novel properties of homomeric beta 1 gamma-aminobutyric acid type A receptors: actions of the anesthetics propofol and pentobarbital. Mol Pharmacol. 1995;47:213–7.PubMed
20.
Jones MV, Harrison NL, Pritchett DB, Hales TG. Modulation of the GABAA receptor by propofol is independent of the gamma subunit. J Pharmacol Exp Ther. 1995;274:962–8.PubMed
21.
Lam DW, Reynolds JN. Modulatory and direct effects of propofol on recombinant GABAA receptors expressed in xenopus oocytes: influence of alpha- and gamma2-subunits. Brain Res. 1998;784:179–87.PubMedCrossRef
22.
Sanna E, Murgia A, Casula A, Biggio G. Differential subunit dependence of the actions of the general anesthetics alphaxalone and etomidate at gamma-aminobutyric acid type A receptors expressed in Xenopus laevis oocytes. Mol Pharmacol. 1997;51:484–90.PubMed
23.
Kay B, Rolly G. I.C.I. 35868, a new intravenous induction agent. Acta Anaesthesiol Belg. 1977;28:303–16.PubMed
24.
Chen S, Rex D. Registered nurse-administered propofol sedation for endoscopy. Aliment Pharmacol Ther. 2004;19:147–55.PubMedCrossRef
25.
Ansley DM, Raedschelders K, Choi PT, et al. Propofol cardioprotection for on-pump aortocoronary bypass surgery in patients with type 2 diabetes mellitus (PRO-TECT II): a phase 2 randomized-controlled trial. Can J Anesth. 2016;63:442–53.PubMedCrossRef
26.
De Cosmo G, Cancelli I, Adduci A, et al. Changes in the hemodynamics during isoflurane and propofol anesthesia: a comparative study. Neurol Res. 2005;27:433–5.PubMedCrossRef
27.
Johnston A, Steiner L, Chatfield D, et al. Effects of propofol on cerebral oxygenation and metabolism after head injury. Br J Anaesth. 2003;91(6):781–6.PubMedCrossRef
28.
Absalom AR, Struys M. An overview of TCI and TIVA. Ghent: Academia Press; 2005.
29.
Aglio L, Lekowski R, Urman R. Essential clinical anesthesia review. Cambridge: Cambridge University Press; 2015.CrossRef
30.
Russell D, Wilkes MP, Hunter SC, et al. Manual compared with target-controlled infusion of propofol. Br J Anaesth. 1995;75:562–6.PubMedCrossRef
31.
Absalom A, Kenny G. Closed-loop control of propofol anaesthesia using bispectral index: performance assessment in patients receiving computer-controlled propofol and manually controlled remifentanil infusions for minor surgery. B J Anaesth. 2003;90(6):737–41.CrossRef
32.
Leslie K, Clavisi O, Hargrove J. Target-controlled infusion versus manually-controlled infusion of propofol for general anaesthesia or sedation in adults. Cochrane Database Syst Rev 2008;(3):CD006059.
33.
Bachmann-Mennanga B, Ohlmer A, Heesen M. Incidence of pain after intravenous injection of a medium-/long-chain triglyceride emulsion of propofol. An observational study in 1375 patients. Arzneimittelforschung. 2003;53:621–6.
34.
Fischer MJ, Leffler A, Niedermirtl F, et al. The general anesthetic propofol excites nociceptors by activating TRPV1 and TRPA1 rather than GABAA receptors. J Biol Chem. 2010;285:34781–92.PubMedPubMedCentralCrossRef
35.
Ebert TJ. Sympathetic and hemodynamic effects of moderate and deep sedation with propofol in humans. Anesthesiology. 2005;103:20–4.PubMedCrossRef
36.
Blouin RT, Seifert HA, Babenco HD, et al. Propofol depresses the hypoxic ventilator response during conscious sedation and isohypercapnia. Anesthesiology. 1993;79:1177–82.PubMedCrossRef
37.
Nieuwenhuijs D, Sarton E, Teppema LJ, Dahan A. Propofol for monitored anesthesia care: implications on hypoxic control of cardiorespiratory responses. Anesthesiology. 2000;92:46–54.PubMedCrossRef
38.
39.
40.
Crowther J, Hrazdil J, Jolly DT, et al. Growth of micro-organisms in propofol, thiopental, and a 1:1 mixture of propofol and thiopental. Anesth Analg. 1996;82:475–8.PubMed
41.
Wachowski I, Jolly DT, Hrazdil J, et al. The growth of microorganisms in propofol and mixtures of propofol and lidocaine. Anesth Analg. 1999;88:209–12.PubMed
42.
McHugh GJ, Roper GM. Propofol emulsion and bacterial contamination. Can J Anaesth. 1995;42:801–4.PubMedCrossRef
43.
Langevin PB, Gravenstein N, Doyle TJ, et al. Growth of Staphylococcus aureus in diprivan and intralipid implications on the pathogenesis of infection. Anesthesiology. 1999;91:1394–400.PubMedCrossRef
44.
Lundy JS. Intravenous anesthesia: preliminary report of the use of two new thiobarbiturates. Proc Mayo Clin. 1935;10:536–43.
45.
Chernish SM, Gruber CM, Demeyer M, Littlefield S, Stoeling VK. Double blind comparison of compound 22451, pentothal and surital. Fed Proc. 1956;15:409.
46.
Hooten WM, Rasmussen KG. Effects of general anesthetic agents in adults receiving electroconvulsive therapy: a systematic review. J ECT. 2008;24:208–23.PubMedCrossRef
47.
48.
Drafts BC, Fisher JL. Identification of structures within GABAA receptor alpha subunits that regulate the agonist action of pentobarbital. J Pharmacol Exp Ther. 2006;318:1094–101.PubMedCrossRef
49.
Bieda MC, Su H, Maciver MB. Anesthetics discriminate between tonic and phasic gamma-aminobutyric acid receptors on hippocampal CA1 neurons. Anesth Analg. 2009;108:484–90.PubMedPubMedCentralCrossRef
50.
51.
Ioannides C, Parke DV. Mechanism of induction of hepatic microsomal drug metabolizing enzymes by a series of barbiturates. J Pharm Pharmacol. 1975;27(10):739–46.PubMedCrossRef
52.
Christensen JH, Andreasen F, Jansen J. Pharmacokinetics and pharmacodynamics of thiopental in patients undergoing renal transplantation. Acta Anaesthesiol Scand. 1983;27(6):513–8.PubMedCrossRef
53.
Dundee JW, McCleery WN, McLoughlin G. The hazard of thiopental anaesthesia in porphyria. Anesth Analg. 1962;41:567–74.PubMedCrossRef
54.
55.
Cordato DJ, Herkes GK, Mather LE, et al. Prolonged thiopentone infusion for neurosurgical emergencies: usefulness of therapeutic drug monitoring. Anaesth Intensive Care. 2001;29(4):339–48.PubMed
56.
Godefroi EF, Jansen PA, Ven Der Eychen CA, et al. dl-1-(1-Arylalkyl)imidazole-5-carboxylate esters: a novel type of hypotic agents. J Med Chem. 1965;8:220–3.PubMedCrossRef
57.
Doenicke A. Etomidate, a new intravenous hypnotic. Acta Anaesthesiol Belg. 1974;25(3):307–15.PubMed
58.
Thyagarajan R, Ramanjaneyulu R, Ticku MK. Enhancement of diazepam and gamma-aminobutyric acid binding by (+)etomidate and pentobarbital. J Neurochem. 1983;41:578–85.PubMedCrossRef
59.
Hill-Venning C, Belelli D, Peters JA, Lambert JJ. Subunit-dependent interaction of the general anaesthetic etomidate with the gamma-aminobutyric acid type A receptor. Br J Pharmacol. 1997;120:749–56.PubMedPubMedCentralCrossRef
60.
Gooding JM, Corssen G. Effect of etomidate on the cardiovascular system. Anesth Analg. 1977;56:717–9.PubMed
61.
Uchida I, Kamatchi G, Burt D, Yang J. Etomidate potentiation of GABAA receptor gated current depends on the subunit composition. Neurosci Lett. 1995;185:203–6.PubMedCrossRef
62.
Ledingham IM, Watt I. Influence of sedation on mortality in critically ill multiple trauma patients. Lancet. 1983;321:1270.CrossRef
63.
Watt I, Ledingham IM. Mortality amongst multiple trauma patients admitted to an intensive therapy unit. Anaesthesia. 1984;39:973–81.PubMedCrossRef
64.
Wagner RL, White PF, Kan PB, Rosenthal MH, Feldman D. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med. 1984;310:1415–21.PubMedCrossRef
65.
Wagner RL, White PF. Etomidate inhibits adrenocortical function in surgical patients. Anesthesiology. 1984;61:647–51.PubMedCrossRef
66.
Jackson WL. Should we use etomidate as an induction agent for endotracheal intubation in patients with septic shock? A critical appraisal. Chest. 2005;127:1031–8.PubMedCrossRef
67.
Walls RM, Murphy MF. Clinical controversies: etomidate as an induction agent for endotracheal intubation in patients with sepsis: continue to use etomidate for intubation of patients with septic shock. Ann Emerg Med. 2008;52:13–4.PubMedCrossRef
68.
Groth C, Acquista N, Khadem T. Current practices and safety of medication use during rapid sequence intubation (RSI). Crit Care Med. 2015;43(12):147.CrossRef
69.
Ball CM, Westhorpe RN. Intravenous induction agents: etomidate. Anaesth Intens Care. 2002;30(4):405.
70.
Johnstone M. The human cardiovascular response to fluothane anaesthesia. Br J Anaesth. 1956;28:392.PubMedCrossRef
71.
Bovill JG. Inhalational anaesthesia: from diethyl ether to xenon. In: Schuttler J, Schwilden H, editors. Handbook of experimental pharmacology. Berlin: Springer; 2008. p. 122–42.
72.
Smith I, Nathanson M, White PF. Sevoflurane—a long-awaited volatile anaesthesia. Br J Anaesth. 1996;76:435–45.PubMedCrossRef
73.
Mihic SJ, Ye Q, Wick MJ, et al. Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors. Nature. 1997;389:385–9.PubMedCrossRef
74.
Jenkins A, Greenblatt EP, Faulkner HJ, et al. Evidence for a common binding cavity for three general anesthetics within the GABAA receptor. J Neurosci. 2001;21(RC136):1–4.
75.
76.
Wheeler DM, Katz A, Rice RT, Hansford RG. Volatile anesthetic effects on sarcoplasmic reticulum calcium content and sarcolemmal calcium flux in isolated rat cardiac cell suspensions. Anesthesiology. 1994;80:372–82.PubMedCrossRef
77.
Van den Elsen M, Sarton E, Teppema L, Berkenbosch A, Dahan A. Influence of 0.1 minimum alveolar concentration of sevoflurane, desflurane and isoflurane on dynamic ventilatory response to hypercapnia in humans. Br J Anaesth. 1998;80:174–82.PubMedCrossRef
78.
79.
Kenna JG, van Pelt FN. The metabolism and toxicity of inhaled anaesthetic agents. Anaesth Pharmacol Rev. 1994;2:29–42.
80.
Page C, Hoffman BB, Curtis M. Integrated pharmacology. 3rd ed. Philadelphia: Mosby; 2006.
81.
Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Handb Exp Pharm. 2008;182:335–60.CrossRef
82.
83.
Kelly MD, Smith A, Banks G, et al. Role of the histidine residue at position 105 in the human alpha 5 containing GABA(A) receptor on the affinity and efficacy of benzodiazepine site ligands. Br J Pharmacol. 2002;135(1):248–56.PubMedPubMedCentralCrossRef
84.
85.
Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature. 1999;401(6755):796–800.PubMedCrossRef
86.
Kaufmann WA, Humpel C, Alheid GF, Marksteiner J. Compartmentation of alpha 1 and alpha 2 GABA(A) receptor subunits within rat extended amygdala: implications for benzodiazepine action. Brain Res. 2003;964(1):91–9.PubMedCrossRef
87.
Crestani F, Löw K, Keist R, et al. Molecular targets for the myorelaxant action of diazepam. Mol Pharmacol. 2001;59(3):442–5.PubMed
88.
Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008;182:335–60.CrossRef
89.
Sarasin DS, Ghoneim MM, Block RI. Effects of sedation with midazolam or propofol on cognition and psychomotor functions. J Oral Maxillofac Surg. 1996;54:1187–93.PubMedCrossRef
90.
Kestin IG, Harvey PB, Nixon C. Psychomotor recovery after three methods of sedation during spinal anaesthesia. Br J Anaesth. 1990;64:675–8.PubMedCrossRef
91.
Ibrahim AE, Taraday JK, Kharasch ED. Bispectral index monitoring during sedation with sevoflurane, midazolam, and propofol. Anesthesiology. 2001;95:1151–9.PubMedCrossRef
92.
Nilsson A, Persson MP, Hartvig P. Effects of the benzodiazepine antagonist flumazenil on postoperative performance following total intravenous anaesthesia with midazolam and alfentanil. Acta Anaesthesiol Scand. 1988;32:441–6.PubMedCrossRef
93.
Johnson KB. New horizons in sedative hypnotic drug development: fast, clean, and soft. Anesth Analg. 2012;115(2):220–2.PubMedCrossRef
94.
95.
Buchwald P, Bodor N. Recent advances in the design and development of soft drugs. Pharmazie. 2014;69:403–13.PubMed
96.
97.
Lee M (MD), NYU Langone Medical Centre (US). Preventing propofol injection pain: prospective randomized trial comparing propofol versus fospropofol [ClinicalTrials.gov identifier NCT01401049]. 2015 Mar 30. National Institutes of Health, ClinicalTrials.gov. https://​clinicaltrials.​gov/​ct2/​show/​NCT01401049. Accessed 30 Mar 2017.
98.
Welliver M, Rugari SM. New drug, fospropofol disodium: a propofol prodrug. AANA J. 2009;77(4):301–8.PubMed
99.
Brohan J, Lee P. Newer drugs for sedation: soft pharmacology. In: Goudra BG, Singh PM, editors. Out of operating room anesthesia: a comprehensive review. Cham: Springer; 2017.
100.
Abdelmalak B, Khanna A, Tetzlaff J. Fospropofol, a new sedative anesthetic, and its utility in the perioperative period. Curr Pharm Des. 2012;18(38):6241–52.PubMedCrossRef
101.
102.
Mueller SW, Moore GD, MacLaren R. Fospropofol disodium for procedural sedation: emerging evidence of its value? Clin Med Insights Ther. 2010;2:513–22.
103.
104.
Candiotti KA, Gan TJ, Young C, et al. A randomized, open-label study of the safety and tolerability of fospropofol for patients requiring intubation and mechanical ventilation in the intensive care unit. Anesth Analg. 2011;113(3):550–6.PubMed
105.
Fechner J, Ihmsen H, Schuttler J, Jeleazcov C. A randomized open-label phase I pilot study of the safety and efficacy of total intravenous anesthesia with fospropofol for coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2013;27(5):908–15.PubMedCrossRef
106.
Zorrilla-Vaca A, Arevalo JJ, Escandón-Vargas K, Soltanifar D, Mirski MA. Infectious disease risk associated with contaminated propofol anesthesia, 1989–2014. Emerg Infect Dis. 2016;22(6):981–92.PubMedPubMedCentralCrossRef
107.
Dhareshwar SS, Stella VJ. Your prodrug releases formaldehyde: should you be concerned? No! J Pharm Sci. 2008;97:4184–93.PubMedCrossRef
108.
Struys M, Fechner J, Schuttler J, Schwilden H. Erroneously published fospropofol pharmacokinetic–pharmacodynamic data and retraction of the affected publications. Anesthesiology. 2010;112(4):1056–7.PubMedCrossRef
109.
Rex DK, Cohen LB, Kline JK, et al. Fospropofol disodium for minimal-to-moderate sedation during colonoscopy produces clear-headed recovery: results of a phase 3, randomized, double-blind trial. Gastrointest Endosc. 2007;65:AB367.CrossRef
110.
Cohen L, Cattau E, Goetch A, et al. A randomized, double-blind, phase 3 study of fospropofol disodium for sedation during colonoscopy. J Clin Gastroent. 2010;44(5):345–53.PubMed
111.
Silvestri GA, Vincent BD, Wahidi MM, et al. A phase 3, randomized, double-blind study to assess the efficacy and safety of fospropofol disodium injection for moderate sedation in patients undergoing flexible bronchoscopy. Chest. 2009;135:41–7.PubMedCrossRef
112.
113.
Cotten JF, Husain SS, Forman SA, et al. Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression. Anesthesiology. 2009;111:240–9.PubMedPubMedCentralCrossRef
114.
Cotton JF, Le Ge R, Banacos N, et al. Closed-loop continuous infusions of etomidate and etomidate analogs in rats: a comparative study of dosing and the impact on adrenocortical function. Anesthesiology. 2011;115:764–73.CrossRef
115.
Le Ge R, Pejo E, Haburcak M, et al. Pharmacological studies of methoxycarbonyl etomidate’s carboxylic acid metabolite. Anesth Analg. 2012;115(2):305–8.PubMedCrossRef
116.
Pejo E, Ge R, Banacos N, et al. Electroencephalographic recovery, hypnotic emergence, and the effects of metabolite after continuous infusions of a rapidly metabolized etomidate analog in rats. Anesthesiology. 2012;116:1057–65.PubMedPubMedCentralCrossRef
117.
Husain SS, Pejo E, Ge R, et al. Modifying methoxycarbonyl etomidate inter-ester specer optimizes in vitro metabolic stability and in vivo hypnotic potency and duration of action. Anesthesiology. 2012;117(5):1027–36.PubMedPubMedCentralCrossRef
118.
Ge R, Pejo E, Husain SS, et al. Encephalographic and hypnotic recoveries following brief and prolonged infusions of etomidate and optimized soft etomidate analogs. Anesthesiology. 2012;117:1037–43.PubMedPubMedCentralCrossRef
119.
Pejo E, Liu J, Lin X, Raines DE. Distinct hypnotic recoveries after infusions of methoxycarbonyl etomidate and cyclopropyl methoxycarbonyl metomidate: the role of the metabolite. Anesth Analg. 2016;122(4):1008–14.PubMedPubMedCentralCrossRef
120.
Ge R, Pejo E, Gallin H, et al. The pharmacology of cyclopropyl-methoxycarbonyl metomidate: a comparison with propofol. Anesth Analg. 2014;118(3):563–7.PubMedCrossRef
121.
Santer P, Pejo E, Feng Y, et al. Cyclopropyl-methoxycarbonyl metomidate: studies in a lipopolysaccharide inflammatory model of sepsis. Anesthesiology. 2015;123(2):368–76.PubMedCrossRef
122.
Struys MMRF, Valk BI, Eleveld DJ, et al. A phase 1, single-center, double-blind, placebo-controlled study in healthy subjects to assess the safety, tolerability, clinical effects, and pharmacokinetics-pharmacodynamics of intravenous cyclopropyl-methoxycarbonylmetomidate (ABP-700) after a single ascending bolus dose. Anesthesiology. 2017;127(1):20–35.PubMedCrossRef
123.
Pejo E, Cotton JF, Kelly EW, et al. In vivo and in vitro pharmacological studies of methoxycarbonyl-carboetomidate. Anesth Analg. 2012;115(2):297–304.PubMedCrossRef
124.
Cotten JF, Forman SA, Laha JK, et al. Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function. Anesthesiology. 2010;112:637–44.PubMedPubMedCentralCrossRef
125.
Kilpatrick GJ, McIntyre MS, Cox RF, et al. CNS 7056: a novel ultra-short-acting benzodiazepine. Anesthesiology. 2007;107:60–6.PubMedCrossRef
126.
127.
Antonik LJ, Goldwater R, Kilpatrick GJ, et al. A placebo and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part I. Safety, efficacy and basic pharmacokinetics. Anesth Analg. 2012;115:274–83.PubMedCrossRef
128.
Wiltshire HR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A placebo and midazolam-controlled phase I single ascending dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056). Part II: populating pharmacokinetic and pharmacodynamic modeling and simulation. Anesth Analg. 2012;115:284–96.PubMedCrossRef
129.
Worthington MT, Antonik LJ, Goldwater DR, et al. A phase Ib dose-finding study of multiple doses of remimazolam (CNS 7056) in volunteers undergoing colonoscopy. Anesth Analg. 2013;117:1093–100.PubMedCrossRef
130.
Borkett KM, Riff DS, Schwartz HI, et al. A phase II, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy. Anesth Analg. 2015;120(4):771–80.PubMedCrossRef
131.
132.
133.
Harrison NL, Simmonds MA. Modulation of the GABA receptor complex by a steroid anaesthetic. Brain Res. 1984;323:287–92.PubMedCrossRef
134.
135.
Radford SG, Lockyear JA, Simpson PJ. Immunological aspects of adverse reactions to althesin. Br J Anaesth. 1982;54:859–63.PubMedCrossRef
136.
137.
Goodchild CS, Serrao JM, Kolosov A, Boyd BJ. Alphaxolone reformulation: a water-soluble intravenous anesthetic preparation in sulfobutyl-ether-β-cyclodextrin. Anesth Analg. 2015;120:1025–31.PubMedCrossRef
138.
Monagle J, Siu L, Worrell J, et al. A phase 1c trial comparing the efficacy and safety of a new aqueous formulation of alphaxalone with propofol/. Anesth Analg. 2015;121(4):914–24.PubMedPubMedCentralCrossRef
Metadata
Title
The Role of GABA Receptor Agonists in Anesthesia and Sedation
Authors
Janette Brohan
Basavana G. Goudra
Publication date
01-10-2017
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 10/2017
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-017-0463-7

Other articles of this Issue 10/2017

CNS Drugs 10/2017 Go to the issue

Leading Article

Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment

Review Article

Efficacy and Tolerability of Phytomedicines in Multiple Sclerosis Patients: A Review

Original Research Article

Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?

Therapy in Practice

Selecting Rational Drug Combinations in Epilepsy

Original Research Article

Pregabalin Use Among Users of Illicit Drugs: A Cross-Sectional Survey in Southern Germany

Review Article

Do Pharmaceuticals Improve Driving in Individuals with ADHD? A Review of the Literature and Evidence for Clinical Practice